Arrowhead Pharmaceuticals 過去の業績

過去基準チェック /36

Arrowhead Pharmaceuticalsの収益は年間平均-9.3%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間22.6% 37.5%割合で増加しています。 Arrowhead Pharmaceuticalsの自己資本利益率は41.5%であり、純利益率は18.5%です。

主要情報

-9.30%

収益成長率

-6.94%

EPS成長率

Biotechs 業界の成長	17.04%
収益成長率	37.53%
株主資本利益率	41.51%
ネット・マージン	18.54%
前回の決算情報	31 Dec 2025

Recent updates

Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality

Feb 12

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Jan 06

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Dec 02

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Oct 07

Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified

Aug 21

Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles

May 18 Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches.

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

May 14

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns

Feb 10

収支内訳

Arrowhead Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:ARWR 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 25	1,091	202	157	633
30 Sep 25	829	-2	139	593
30 Jun 25	573	-148	129	552
31 Mar 25	545	-144	122	541
31 Dec 24	3	-640	117	512
30 Sep 24	4	-599	113	491
30 Jun 24	20	-539	116	450
31 Mar 24	35	-471	116	393
31 Dec 23	182	-297	108	373
30 Sep 23	241	-205	104	342
30 Jun 23	256	-181	117	320
31 Mar 23	273	-150	125	298
31 Dec 22	278	-155	135	301
30 Sep 22	243	-176	132	289
30 Jun 22	250	-154	141	269
31 Mar 22	263	-112	123	258
31 Dec 21	144	-183	104	228
30 Sep 21	138	-141	85	202
30 Jun 21	108	-126	64	178
31 Mar 21	89	-110	56	151
31 Dec 20	80	-103	55	137
30 Sep 20	88	-85	54	127
30 Jun 20	124	-24	52	105
31 Mar 20	139	10	46	91
31 Dec 19	164	53	35	84
30 Sep 19	169	68	27	81
30 Jun 19	137	46	25	72
31 Mar 19	95	10	23	66
31 Dec 18	47	-29	20	58
30 Sep 18	16	-54	19	53
30 Jun 18	14	-54	18	51
31 Mar 18	22	-44	16	51
31 Dec 17	31	-35	13	54
30 Sep 17	31	-34	20	49
30 Jun 17	23	-46	25	49
31 Mar 17	13	-60	32	46
31 Dec 16	4	-75	42	40
30 Sep 16	0	-82	25	61
30 Jun 16	0	-84	41	39
31 Mar 16	0	-81	40	37
31 Dec 15	0	-89	36	39
30 Sep 15	0	-92	35	47
30 Jun 15	0	-90	32	45
31 Mar 15	0	-85	30	44

質の高い収益: ARWRは高品質の収益を持っています。

利益率の向上: ARWR過去に利益を上げました。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ARWR過去 5 年間で収益を上げており、収益は年間-9.3%増加しています。

成長の加速: ARWRは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: ARWR昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 52.4% ) と比較することは困難です。

株主資本利益率

高いROE: ARWRの自己資本利益率 ( 41.51% ) は抜群ですが、負債レベルが高いためこの指標は歪んでいます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/02/24 16:57
終値	2026/02/24 00:00
収益	2025/12/31
年間収益	2025/09/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用された分析モデルの詳細は弊社の Githubページでご覧いただけます。また、レポートの利用方法に関するガイドと YouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Arrowhead Pharmaceuticals, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。27

アナリスト	機関
Ying Huang	Barclays
William Pickering	Bernstein
Jason Matthew Gerberry	BofA Global Research

Arrowhead Pharmaceuticals 過去の業績

過去 基準チェック /36

主要情報

最近の業績更新

Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Arrowhead Pharmaceuticals, Inc. to Report Q1, 2026 Results on Feb 05, 2026

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Full year 2024 earnings: EPS and revenues miss analyst expectations

Recent updates

Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality

Consensus revenue estimates increase by 12%, EPS downgraded

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Arrowhead Pharmaceuticals, Inc. to Report Q1, 2026 Results on Feb 05, 2026

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 19, 2026

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.998502 million.

Price target increased by 15% to US$75.91

Arrowhead Pharmaceuticals Announces Nmpa Approval of Redemplo (Plozasiran) for Familial Chylomicronemia Syndrome in China

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Arrowhead Pharmaceuticals Announces Health Canada Approval of Redemplo to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Chairman notifies of intention to sell stock

Chairman recently sold US$12m worth of stock

Chairman notifies of intention to sell stock

Now 20% overvalued after recent price rise

Independent Director recently sold US$992k worth of stock

Price target increased by 7.4% to US$59.25

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Independent Director recently sold US$493k worth of stock

Arrowhead Pharmaceuticals, Inc. Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Independent Director notifies of intention to sell stock

New minor risk - Share price stability

Consensus estimates of losses per share improve by 87%

Price target increased by 16% to US$55.00

Arrowhead Pharmaceuticals, Inc Announces FDA Approval of Redemplo (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Consensus EPS estimates fall by 221%

Arrowhead Pharmaceuticals, Inc. Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Files Complaint for Patent Infringement Against Arrowhead Pharmaceuticals, Inc

Consensus EPS estimates have been downgraded.

Arrowhead Pharmaceuticals, Inc. Requests Regulatory Clearance to Initiate Phase 1/2A Study of Aro-Mapt for the Treatment of Alzheimer's Disease and Other Tauopathies

No longer forecast to breakeven

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Consensus EPS estimates fall by 65%

Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified

Consensus EPS estimates fall from profit to US$0.11 loss, revenue upgraded

No longer forecast to breakeven

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Forecast to breakeven in 2025

Arrowhead Pharmaceuticals Completes Enrollment in Shasta-3, Shasta-4, and Muir-3 Phase 3 Studies of Plozasiran

Consensus EPS estimates increase by 17%

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of Aro-Alk7 for the Treatment of Obesity

Insufficient new directors

Consensus EPS estimates increase by 168%

Forecast to breakeven in 2025

Consensus revenue estimates increase by 112%

Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

New major risk - Revenue and earnings growth

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective May 13, 2025

Chairman recently sold US$1.5m worth of stock

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Is Finally Arriving

Chairman recently sold US$775k worth of stock

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals, Inc. Presents Preclinical Data on Aro-Alk7 for Treatment of Obesity

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns

Arrowhead Pharmaceuticals, Inc. Appoints Douglas Ingram as Director

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2025

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

過去基準チェック /36